Non Small Cell Lung Cancer (NSCLC)

Stage I-III: Unresectable

Stage I-III

Treated w/ SBRT +/- adjuvant chemo

LUN0115
Phase II Adjuvant Durvalumab in Early Stage NSCLC Patients with ctDNA Minimal Residual Disease

Pl: Neal Stanford

Stage II-III

LUN0114
Personalized Escalation of Consolidation Treatment After ChemoRT & Immunotherapy in Stage II/III NSCLC

Pl: Neal Stanford

LUN0118
Phase III Atezolizumab & Tiragolumab vs Durvalumab in Stage III NSCLC w/o Progression After Chemoradiation

Pl: Wakelee Pending

Stage I-IV

VAR0203
Performance and Safety of Biology-Guided Radiotherapy using the Reflexion Medical Radiotherapy System

Pl: Chang Stanford

KEY

Pending

Open for Enrollment

Observational Study

Link

Trial Posting

Enrollment on Hold

Extension Study

Immunotherapy